

LITERATÚRA

1. AlSharoqi IA, Aljumah M, Bohlega S, et al. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. *Neural Ther.* 2020;9(1):55-66.
2. Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis. The MIRROR study. *Neurology.* 2018;90(20):e1805-e1814.
3. Brod SA. The genealogy, methodology, similarities, and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica. *Autoimmun Rev.* 2022;21(10):103170.
4. CAMMS223 Trial Investigators, Coles AJ, Compston DAS, Selma J, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. *N Engl J Med.* 2008;359:1786-801.
5. Clerico M, Artusi CA, Di Liberto A, et al. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis. *Expert Opin Drug Saf.* 2017;16:963-72.
6. Cohen JA, Coles AJ, Arnold DL et al. Alemtuzumab vs. interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. *Lancet.* 2012;380:1819-1828.
7. Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. *Neurology.* 2017;89(11):1117-1126.
8. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *The Lancet.* 2012;380(9856):1829-1839.
9. Comi G, Cook S, Rammohan K, et al. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. *Ther Adv Neurol Disord.* 2018;11:175628561775(3365).
10. Comi G, O'Connor P, Montalban X, et al; FTY720D2201 Study Group. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. *Mult Scler.* 2010;16(2):197-207.
11. Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurol.* 2014;13:247-56. doi:10.1016/S1474-4422(13)70308-9.
12. De Sèze J, Suchet L, Mekies, C. et al. The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus. *Neural Ther.* 2023;12:351-369.
13. Förster M, Graf J, Mares J, et al. Drug treatment of clinically isolated syndrome. *CNS Drugs.* 2019;33:659-676.
14. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. *N Engl J Med.* 2010;362:416-26. doi:10.1056/NEJMoa0902533.
15. Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. *Mult Scler.* 2017;24:1594-604. doi: 10.1177/1352458517727603.
16. Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. *JAMA Neurol.* 2019;76:536-541.
17. Hauser SL, Bar-Or A, Cohen JA, et al. ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. *N Engl J Med.* 2020;383(6):546-557.
18. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. *N Engl J Med.* 2017;376:221-34. doi: 10.1056/NEJMoa1601277.
19. Havrdova E, Douglas DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up. Durable efficacy in the absence of continuous MS therapy. *Neurology.* 2017;89(11):1107-1116.
20. Heckova E, Dal-Bianco A, Strasser B, et al. Extensive Brain Pathologic Alterations Detected with 7.0-T MR Spectroscopic Imaging Associated with Disability in Multiple Sclerosis. *Radiology.* 2022;303(1):141-150. doi: 10.1148/radiol.210614.
21. Ingwersen J, Aktas O, Hartung HP. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. *Neurotherapeutics.* 2016;13(1):47-57.
22. Kappos L, Antel J, Comi G, et al; FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. *N Engl J Med.* 2006;355(11):1124-1140.
23. Kappos L, Bar-Or A, Cree BAC, et al. EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *Lancet.* 2018;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6.
24. Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. *JAMA Neurol.* 2021;78:558-567.
25. Kappos L, Radue EW, O'Connor P, et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *New Engl J Med.* 2010;362(5):387-401.
26. Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. *JAMA Neurol.* 2020;77:1132-1140.
27. Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. *Mult Scler.* 2017;23:1233-1240.
28. Leist TP, Comi G, Cree BAC, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLEMS): a phase 3 randomised trial. *Lancet Neurol.* 2014;13:257-67.
29. Lisý L. Individualizácia pacienta pri výbere vhodnej liečby sclerosis multiplex. *Via pract.* 2016; 13(5):191-194.
30. Lünemann JD, Ruck T, Muraro PA, et al. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. *Nat Rev Neurol.* 2020;16(1):56-62. doi: 10.1038/s41582-019-0268-z.
31. Mallucci G, Annovazzi P, Miente S, et al. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. *J Neurol.* 2018;265:1850-9.
32. McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. *J Neurol Neurosurg Psychiatry.* 2016;87:117-25.
33. Miclea A, Leussink VI, Hartung HP, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. *J Neurol.* 2016;263:1626-32.
34. Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL, Castelijns JA. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. *Arch Neurol.* 2004;61(2):217-221.
35. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. *N Engl J Med.* 2017;376:209-20. doi: 10.1056/NEJMoa1606468.
36. Newsome S, Krzystanek E, Selma J, et al. Subcutaneous ocrelizumab in patients with multiple sclerosis: results of the phase III OCARINA II study. *J Neurol Neurosurg Psychiatry.* 2024;95:A14.
37. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. *N Engl J Med.* 2011;365:1293-303. doi: 10.1056/NEJMoa1014656.
38. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med.* 2006; 354:899-910.
39. Rommer PS, Milo R, Han MH, et al. Immunological Aspects of Approved MS Therapeutics. *Front Immunol.* 2019;10:1564. doi: 10.3389/fimmu.2019.01564.
40. Ruggieri S, Quartuccio ME, Prosperini L. Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data. *Degener Neurol Neuromuscul Dis.* 2022;12:61-73.
41. Rudick RA, StuartWH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. *N Engl J Med.* 2006;354:911-23. doi: 10.1056/NEJMoa044396.
42. Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. *Nat Rev Neurol.* 2015;11:379-389.
43. Selma J, Cree BAC, Barnett M, et al. Multiple sclerosis: time for early treatment with high-efficacy drugs. *J Neurol.* 2024;271(1):105-115. doi: 10.1007/s00415-023-11969-8.
44. Sellner J, Rommer PS. Immunological consequences of „immune reconstitution therapy“ in multiple sclerosis: A systematic review. *Autoimmun Rev.* 2020;102492.
45. Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. *Neurology.* 2014;82(7):573-81.
46. Stüve O. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. *J Neurol Sci.* 2008 Nov 15;274(1-2):39-41. doi: 10.1016/j.jns.2008.03.022.
47. Stüve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. *Arch Neurol.* 2006 Oct;63(10):1383-7. doi: 10.1001/archneur.63.10.1383.
48. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol.* 2018;17(2):162-173.
49. Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: A randomised, controlled phase 3 trial. *Mult Scler.* 2014;20(6):705-716.
50. Vigiotta V, Miller D, Bar-Or A, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. *Ann Clin Transl Neurol.* 2015;2:103-18. doi:10.1002/acn3.148.